Ann Coloproctol > Volume 39(4); 2023 > Article |
|
Variable |
Before PSM |
After PSM |
||||
---|---|---|---|---|---|---|
High CAR (≥0.038) | Low CAR (<0.038) | P-value | High CAR (≥0.038) | Low CAR (<0.038) | P-value | |
No. of patients | 144 | 176 | 93 | 93 | ||
Sex | ||||||
Male | 86 (59.7) | 81 (46.0) | 53 (57.0) | 53 (57.0) | ||
Female | 58 (40.3) | 95 (54.0) | 0.018 | 40 (43.0) | 40 (43.0) | >0.999 |
Age (yr) | 73.8±10.8 | 68.6±11.8 | <0.001 | 71.9±11.8 | 71.4±10.5 | 0.738 |
ASA PS classification | ||||||
I | 7 (4.9) | 25 (14.2) | 7 (7.5) | 2 (2.2) | ||
II | 87 (60.4) | 124 (70.5) | 58 (62.4) | 69 (74.2) | ||
III | 49 (34.0) | 27 (15.3) | 27 (29.0) | 22 (23.7) | ||
IV | 1 (0.7) | 0 (0) | <0.001 | 1 (1.1) | 0 (0) | 0.114 |
CEA (ng/mL) | ||||||
≤5 | 74 (51.4) | 123 (69.9) | 51 (54.8) | 55 (59.1) | ||
>5 | 70 (48.6) | 53 (30.1) | 0.001 | 42 (45.2) | 38 (40.9) | 0.657 |
CA19-9 (U/mL) | ||||||
≤35 | 114 (79.2) | 152 (86.4) | 76 (81.7) | 74 (79.6) | ||
>35 | 30 (20.8) | 24 (13.6) | 0.100 | 17 (18.3) | 19 (20.4) | 0.853 |
Tumor location | ||||||
Right-side | 52 (36.1) | 73 (41.5) | 34 (36.6) | 34 (36.6) | ||
Left-side | 92 (63.9) | 103 (58.5) | 0.358 | 59 (63.4) | 59 (63.4) | >0.999 |
Tumor size (mm) | ||||||
≤50 | 76 (52.8) | 149 (84.7) | 69 (74.2) | 68 (73.1) | ||
>50 | 68 (47.2) | 27 (15.3) | <0.001 | 24 (25.8) | 25 (26.9) | >0.999 |
Tumor histotype | ||||||
pap/tub | 133 (92.4) | 170 (96.6) | 89 (95.7) | 87 (93.5) | ||
muc/por/sig | 11 (7.6) | 6 (3.4) | 0.132 | 4 (4.3) | 6 (6.5) | 0.747 |
Lymphatic invasion | ||||||
No | 65 (45.1) | 104 (59.1) | 50 (53.8) | 47 (50.5) | ||
Yes | 79 (54.9) | 72 (40.9) | 0.014 | 43 (46.2) | 46 (49.5) | 0.769 |
Venous invasion | ||||||
No | 70 (48.6) | 118 (67.0) | 53 (57.0) | 54 (58.1) | ||
Yes | 74 (51.4) | 58 (33.0) | 0.001 | 40 (43.0) | 39 (41.9) | >0.999 |
Pathological stage | ||||||
0 | 5 (3.5) | 29 (16.5) | 5 (5.4) | 7 (7.5) | ||
I | 24 (16.7) | 56 (31.8) | 24 (25.8) | 23 (24.7) | ||
II | 68 (47.2) | 45 (25.6) | 35 (37.6) | 30 (32.3) | ||
III | 47 (32.6) | 46 (26.1) | <0.001 | 29 (31.2) | 33 (35.5) | 0.805 |
Postoperative complicationa | 13 (9.0) | 12 (6.8) | 0.533 | 7 (7.5) | 9 (9.7) | 0.795 |
Values are presented as number only, number (%), or mean±standard deviation.
CRC, colorectal cancer; CAR, C-reactive protein to albumin ratio; PSM, propensity score matching; ASA, American Society of Anesthesiologists; PS, physical status; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9; pap, papillary; tub, tubular; muc, mucinous; por, poorly differentiated; sig, signet-ring cell.
Variable |
Before PSM |
After PSM |
||||
---|---|---|---|---|---|---|
High CAR (≥2.007) | Low CAR (<2.007) | P-value | High CAR (≥2.007) | Low CAR (<2.007) | P-value | |
No. of patients | 95 | 225 | 81 | 81 | ||
Sex | ||||||
Male | 45 (47.4) | 122 (54.2) | 43 (53.1) | 43 (53.1) | ||
Female | 50 (52.6) | 103 (45.8) | 0.273 | 38 (46.9) | 38 (46.9) | >0.999 |
Age (yr) | 74.0±11.2 | 69.7±11.6 | 0.002 | 72.4±11.1 | 73.5±10.4 | 0.511 |
ASA PS classification | ||||||
I | 7 (7.4) | 25 (11.1) | 7 (8.6) | 7 (8.6) | ||
II | 50 (52.6) | 161 (71.6) | 45 (55.6) | 48 (59.3) | ||
III | 38 (40.0) | 38 (16.9) | 29 (35.8) | 25 (30.9) | ||
IV | 0 (0) | 1 (0.4) | <0.001 | 0 (0) | 1 (1.2) | 0.813 |
CEA (ng/mL) | ||||||
≤5 | 46 (48.4) | 151 (67.1) | 44 (54.3) | 48 (59.3) | ||
>5 | 49 (51.6) | 74 (32.9) | 0.002 | 37 (45.7) | 33 (40.7) | 0.634 |
CA19-9 (U/mL) | ||||||
≤35 | 74 (77.9) | 192 (85.3) | 65 (80.2) | 66 (81.5) | ||
> 35 | 21 (22.1) | 33 (14.7) | 0.141 | 16 (19.8) | 15 (18.5) | >0.999 |
Tumor location | ||||||
Right-side | 43 (45.3) | 82 (36.4) | 33 (40.7) | 28 (34.6) | ||
Left-side | 52 (54.7) | 143 (63.6) | 0.168 | 48 (59.3) | 53 (65.4) | 0.517 |
Tumor size (mm) | ||||||
≤50 | 54 (56.8) | 171 (76.0) | 51 (63.0) | 49 (60.5) | ||
> 50 | 41 (43.2) | 54 (24.0) | 0.001 | 30 (37.0) | 32 (39.5) | 0.872 |
Tumor histotype | ||||||
pap/tub | 86 (90.5) | 217 (96.4) | 76 (93.8) | 76 (93.8) | ||
muc/por/sig | 9 (9.5) | 8 (3.6) | 0.052 | 5 (6.2) | 5 (6.2) | >0.999 |
Lymphatic invasion | ||||||
No | 38 (40.0) | 131 (58.2) | 36 (44.4) | 32 (39.5) | ||
Yes | 57 (60.0) | 94 (41.8) | 0.003 | 45 (55.6) | 49 (60.5) | 0.633 |
Venous invasion | ||||||
No | 45 (47.4) | 143 (63.6) | 41 (50.6) | 39 (48.1) | ||
Yes | 50 (52.6) | 82 (36.4) | 0.009 | 40 (49.4) | 42 (51.9) | 0.875 |
Pathological stage | ||||||
0 | 9 (9.5) | 25 (11.1) | 9 (11.1) | 4 (4.9) | ||
I | 16 (16.8) | 64 (28.4) | 16 (19.8) | 16 (19.8) | ||
II | 32 (33.7) | 81 (36.0) | 22 (27.2) | 37 (45.7) | ||
III | 38 (40.0) | 55 (24.4) | 0.026 | 34 (42.0) | 24 (29.6) | 0.060 |
Postoperative complicationa | 13 (13.7) | 12 (5.3) | 0.020 | 11 (13.6) | 2 (2.5) | 0.009 |
Values are presented as number only, number (%), or mean±standard deviation.
CRC, colorectal cancer; CAR, C-reactive protein to albumin ratio; PSM, propensity score matching; ASA PS, American Society of Anesthesiologists physical status; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9; pap, papillary; tub, tubular; muc, mucinous; por, poorly differentiated; sig, signet-ring cell.
Variable |
Before PSM |
After PSM |
||||
---|---|---|---|---|---|---|
High CAR (≥0.859) | Low CAR (<0.859) | P-value | High CAR (≥0.859) | Low CAR (<0.859) | P-value | |
No. of patients | ||||||
Sex | 75 | 245 | 72 | 72 | ||
Male | 52 (69.3) | 115 (46.9) | 49 (68.1) | 54 (75.0) | ||
Female | 23 (30.7) | 130 (53.1) | 0.001 | 23 (31.9) | 18 (25.0) | 0.460 |
Age (yr) | 74.3±9.6 | 69.9±12.0 | 0.004 | 74.2±9.7 | 73.4±9.2 | 0.635 |
ASA PS classification | ||||||
I | 2 (2.7) | 30 (12.2) | 2 (2.8) | 1 (1.4) | ||
II | 41 (54.7) | 170 (69.4) | 41 (56.9) | 42 (58.3) | ||
III | 31 (41.3) | 45 (18.4) | 29 (40.3) | 29 (40.3) | ||
IV | 1 (1.3) | 0 (0.0) | <0.001 | 0 (0.0) | 0 (0.0) | >0.999 |
CEA (ng/mL) | ||||||
≤5 | 43 (57.3) | 154 (62.9) | 41 (56.9) | 39 (54.2) | ||
>5 | 32 (42.7) | 91 (37.1) | 0.417 | 31 (43.1) | 33 (45.8) | 0.867 |
CA19-9 (U/mL) | ||||||
≤35 | 64 (85.3) | 202 (82.4) | 61 (84.7) | 56 (77.8) | ||
>35 | 11 (14.7) | 43 (17.6) | 0.725 | 11 (15.3) | 16 (22.2) | 0.393 |
Tumor location | ||||||
Right-side | 29 (38.7) | 96 (39.2) | 28 (38.9) | 28 (38.9) | ||
Left-side | 46 (61.3) | 149 (60.8) | >0.999 | 44 (61.1) | 44 (61.1) | >0.999 |
Tumor size (mm) | ||||||
≤50 | 48 (64.0) | 177 (72.2) | 46 (63.9) | 49 (68.1) | ||
>50 | 27 (36.0) | 68 (27.8) | 0.194 | 26 (36.1) | 23 (31.9) | 0.725 |
Tumor histotype | ||||||
pap/tub | 71 (94.7) | 232 (94.7) | 68 (94.4) | 69 (95.8) | ||
muc/por/sig | 4 (5.3) | 13 (5.3) | >0.999 | 4 (5.6) | 3 (4.2) | >0.999 |
Lymphatic invasion | ||||||
No | 35 (46.7) | 134 (54.7) | 33 (45.8) | 37 (51.4) | ||
Yes | 40 (53.3) | 111 (45.3) | 0.236 | 39 (54.2) | 35 (48.6) | 0.617 |
Venous invasion | ||||||
No | 40 (53.3) | 148 (60.4) | 38 (52.8) | 45 (62.5) | ||
Yes | 35 (46.7) | 97 (39.6) | 0.286 | 34 (47.2) | 27 (37.5) | 0.312 |
Pathological stage | ||||||
0 | 6 (8.0) | 28 (11.4) | 6 (8.3) | 8 (11.1) | ||
I | 14 (18.7) | 66 (26.9) | 13 (18.1) | 19 (26.4) | ||
II | 32 (41.7) | 81 (33.1) | 30 (41.7) | 23 (31.9) | ||
III | 23 (30.7) | 70 (28.6) | 0.297 | 23 (31.9) | 22 (30.6) | 0.510 |
Postoperative complicationa | 17 (23.3) | 8 (3.3) | <0.001 | 16 (22.9) | 3 (4.2) | 0.001 |
Values are presented as number only, number (%), or mean±standard deviation.
CRC, colorectal cancer; CAR, C-reactive protein to albumin ratio; PSM, propensity score matching; ASA PS, American Society of Anesthesiologists physical status; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9; pap, papillary; tub, tubular; muc, mucinous; por, poorly differentiated; sig, signet-ring cell.
Effect of Gum Chewing on the Recovery From Laparoscopic Colorectal Cancer Surgery2013 December;29(6)